RLAY - CIK 0001812364
Relay Therapeutics, Inc. trades as RLAY and has a market capitalization of $2.60 B, making it the #1914 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $15.36M, up 53.4% from the prior year and net income of -$276.48M. This page tracks Relay Therapeutics, Inc. through 506 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 5 fiscal years Relay Therapeutics, Inc.'s revenue declined from $82.65M to $15.36M, a compound annual decline rate of 28.6%. Net profit margin compressed from -63.4% to -1800.6% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-21 |
| Prospectus supplement | 424B5 | 2026-05-21 |
| Prospectus supplement | 424B5 | 2026-05-19 |
| Major company event | 8-K | 2026-05-19 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Insider sale notice | 144 | 2026-05-14 |
| Insider trade | 4 | 2026-05-14 |
| Quarterly report | 10-Q | 2026-05-05 |
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June | Relay Therapeutics
Relay Therapeutics Announces Pricing of Public Offering of Common Stock | Relay Therapeutics
Relay Therapeutics Announces Proposed Public Offering of Common Stock | Relay Therapeutics
Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies | Relay Therapeutics
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates | Relay Therapeutics
The largest companies sharing Relay Therapeutics, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Relay Therapeutics, Inc. (RLAY) has a market capitalization of $2.60 B as of 2026-06-10, ranking #1914 among US-listed companies.
Relay Therapeutics, Inc. reported revenue of $15.36M for fiscal year 2025, an increase of 53.4% year over year.
In its latest fiscal year Relay Therapeutics, Inc. reported a net loss of $276.48M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.